Amphotericin B/emulsion admixture interactions: An approach concerning the reduction of amphotericin B toxicity

Journal of Pharmaceutical Sciences

Volumn 91, Issue 11, 2002, Pages 2354-2366

  Egito, E Sócrates T ^a,b   Araújo, Ivonete B ^a   Damasceno, Bolivar P G L ^a   Price, James C ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Absorption spectra; Amphotericin B; Candida tropicalis; Parenteral emulsion; Red blood cells; Toxicity; Transmission electron microscopy (TEM)

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; INTRALIPID; LIPOFUNDIN;

ARTICLE; CANDIDA TROPICALIS; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG FORMULATION; DRUG TOXICITY; EMULSION; PARTICLE SIZE;

EID: 0036827786     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10223     Document Type: Article

References (49)

1. de Pauw BE, Meunier F. 1999. The challenge of invasive fungal infection. Chemotherapy 45:1-14.
2. Hartsel S, Bolard J. 1996. Amphotericin B: New life for an old drug. Trends Pharmacol Sci 17:445-449.
3. Gallis HA. 1996. Amphotericin B: A commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clin Infect Dis 22:S145-S147.
4. Groll AH, Muller FMC, Piscitelli SC, Walsh TJ. 1998. Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 210:264-273.
5. Hiemenz JW, Walsh TJ. 1996. Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 22:S133-S144.
6. Joly V, Geoffray C, Reynes J, Goujard C, Mechali D, Maslo C, Raffi F, Yeni P. 1996. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. J Antimicrob Chemother 38:117-126.
7. Wong-Beringer A, Jacobs RA, Guglielmo BJ. 1998. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 27:603-618.
8. Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N, Bugelski P, Poste G. 1988. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 158:1065-1070.
9. Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL. 1992. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 30:535-541.
10. Caillot D, Casasnovas O, Solary E, Chavanet P, Bonnotte B, Reny G, Entezam F, Lopez J, Bonnin A, Guy H. 1993. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 31:161-169.
11. Thakur CP. 1994. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Trans R Soc Trop Med Hyg 88:698-699.
12. Joly V, Farinotti R, Saintjulien L, Cheron M, Carbon C, Yeni P. 1994. In-vitro renal toxicity and in-vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with intralipid. Antimicrob Agents Chemother 38:177-183.
13. Sorkine P, Nagar H, Weinbroum A, Setton A, Israitel E, Scarlatt A, Silbiger A, Rudick V, Kluger Y, Halpern P. 1996. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: Results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med 24:1311-1315.
14. Heinemann V, Kahny B, Jehn U, Muhlbayer D, Debus A, Wachholz K, Bosse D, Kolb HJ, Wilmanns W. 1997. Serum pharmacology of amphotericin B applied in lipid emulsions. Antimicrob Agents Chemother 41:728-732.
15. Shadkhan Y, Segal E, Bor A, Gov Y, Rubin M, Lichtenberg D. 1997. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother 39:655-658.
16. Jensen GM, Skenes CR, Bunch TH, Weissman CA, Amirghahari N, Satorius A, Moynihan KL, Eley CGS. 1999. Determination of the relative toxicity of amphotericin B formulations: A red blood cell potassium release assay. Drug Deliv 6:81-88.
17. Chavanet PY, Garry I, Charlier N, Caillot D, Kisterman JP, Dathis M, Portier H. 1992. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 305:921-925.
18. Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B, Perello L, Dumas M, Entezam F, Guy H. 1994. A controlled trial of the tolerance of amphotericin-B infused in dextrose or in intralipid in with hematological malignancies. J Antimicrob Chemother 33:603-613.
19. Schoffski P, Freund M, Wunder R, Petersen D, Kohne CH, Hecker H, Schubert U, Ganser A. 1998. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: Randomised study. Br Med J 317:379-384.
20. Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW. 1999. Amphotericin B in children with malignant disease: A comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother 43:1417-1423.
21. Gaboriau F, Cheron M, Leroy L, Bolard J. 1997. Physico-chemical properties of the heat-induced 'superaggregates' of amphotericin B. Biophys Chem 66:1-12.
22. Legrand P, Romero EA, Cohen BE, Bolard J. 1992. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother 36:2518-2522.
23. Egito EST, Fessi H, Appel M, Barratt G, Legrand P, Bolard J, Devissaguet JP. 1996. A morphological study of an amphotericin B emulsion-based delivery system. Int J Pharm 145:17-27.
24. Lambing HE, Wolf BD, Hartsel SC. 1993. Temperature effects on the aggregation state and activity of amphotericin B. Biochim Biophys Acta 1152:185-188.
25. Barwicz J, Christian S, Gruda I. 1992. Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother 36:2310-2315.
26. Bolard J, Legrand P, Heitz F, Cybulska B. 1991. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 30:5707-5715.
27. Espuelas MS, Legrand P, Cheron M, Barratt G, Puisieux F, Devissaguet JP, Irache JM. 1998. Interaction of amphotericin B with polymeric colloids: A spectroscopic study. Colloids Surf B Biointerfaces 11:141-151.
28. Mazerski J, Bolard J, Borowski E. 1982. Self-association of some polyene macrolide antibiotics in aqueous media. Biochim Biophys Acta 719:11-17.
29. Mazerski J, Grzybowska J, Borowski E. 1990. Influence of net charge on the aggregation and solubility behavior of amphotericin B and its derivatives in aqueous media. Eur Biophys J 18:159-164.
30. Bolard J, Seigneuret M, Boudet G. 1980. Interaction between phospholipid-bilayer membranes and the polyene antibiotic amphotericin B: Lipid state and cholesterol content dependence. Biochim Biophys Acta 599:280-293.
31. Barwicz J, Gruszecki WI, Gruda I. 1993. Spontaneous organization of amphotericin B in aqueousmedium. J Colloid Interface Sci 158:71-76.
32. Maher P, Singer SJ. 1984. Structural changes in membranes produced by the binding of small amphipathic molecules. Biochemistry 23:232-240.
33. Hartsel SC, Benz SK, Ayenew W, Bolard J. 1994. Na+, K+ and Cl-selectivity of the permeability pathways induced through sterol-containing membrane-vesicles by amphotericin B and other polyene antibiotics. Eur Biophys J 23:125-132.
34. Milhaud J, Hartmann MA, Bolard J. 1989. Interaction of the polyene antibiotic amphotericin-B with model membranes: Differences between small and large unilamellar vesicles. Biochimie 71:49-56.
35. Oneill LJ, Miller JG, Petersen NO. 1986. Evidence for nystatin micelles in L-cell membranes from fluorescence photobleaching measurements of diffusion. Biochemistry 25:177-181.
36. Strauss G, Kral F. 1982. Borate complexes of amphotericin B: Polymeric species and aggregates in aqueous-solutions. Biopolymers 21:459-470.
37. Ernst C, Grange J, Rinnert H, Dupont G. 1981. Structure of amphotericin B aggregates as revealed by UV and CD spectroscopies. Biopolymers 20:1575-1588.
38. Pramauro E, Pelezetti E. 1996. Surfactants in analytical chemistry: Applications of organized amphiphilic media, Vol. 31. New York: Elsevier.
39. Lamyfreund MT, Schreier S, Peitzsch RM, Reed WF. 1991. Characterization and time-dependence of amphotericin B: Deoxycholate aggregation by quasielastic light-scattering. J Pharm Sci 80:262-266.
40. Asher IM, Schwartzman G, USASRG (U.S. Antibiotics Standards Research Group). 1972. Amphotericin B In: Florey K, editor. Analytical Profiles of Drug Substances, Vol. 6. New York: Academic Press, pp 1-42.
41. Washington C, Taylor SJ, Davis SS. 1988. The structure of colloidal formulations of amphotericin B. Int J Pharm 46:25-30.
42. Butler WT, Cotlove E. 1971. Increased permeability of human erythrocytes induced by amphotericin B. J Infect Dis 123:341-350.
43. Davis SS, Washington C, West P, Illum L, Liversidge G, Sternson L, Kirsh R. 1987. Lipid emulsions as drug delivery systems. Ann NY Acad Sci 507:75-88.
44. Forster D, Washington C, Davis SS. 1988. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Pharmacol 40:325-328.
45. Souza LC, Maranhao RC, Schreier S, Campa A. 1993. In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J Antimicrob Chemother 32:123-132.
46. Egito EST, Appel M, Fessi H, Barratt G, Puisieux F, Devissaguet JP. 1996. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. J Antimicrob Chemother 38:485-497.
47. Janoff AS, Perkins WR, Saletan SL, Swenson CE. 1993. Amphotericin B lipid complex (ABLC™: A molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 3:451-471.
48. Jullien S, Contrepois A, Sligh JE, Domart Y, Yeni P, Brajtburg J, Medoff G, Bolard J. 1989. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids. Antimicrob Agents Chemother 33:345-349.
49. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP. 1991. Amphotericin-B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35:615-621.